Neuroblastoma Market Analysis by Treatment Type (Chemotherapy, Immunotherapy); Product Type (Tablets, Vaccines); Distribution Channel (Online, Offline); End User (Hospitals, Clinics) – Global Supply & Demand Analysis & Opportunity Outlook 2023-2035

Buy Now Report ID: 4902 | Published Date: May 02, 2023

Global Neuroblastoma Market Size, Forecast, and Trend Highlights Over 2023 – 2035

Neuroblastoma Market size is estimated to reach ~USD 5,100 Million by the end of 2035 by growing at a CAGR of ~4% over the forecast period, i.e., 2023 – 2035. In addition to this, in the year 2022, the market size of neuroblastoma was ~USD 2900 Million. The growth of the market can be attributed to the increasing incidence of neuroblastoma and the development of new and advanced treatment methods. For instance, neuroblastoma accounts for approximately 8–10% of all cases of childhood cancer. According to statistics, neuroblastoma occurs in 11 to 13 children under the age of 15 per million, and in children 10–14 years of age, the incidence rate rises to 65 per million. Neuroblastoma is a type of cancer that affects the peripheral nervous system, which is made up of nerves that connect the central nervous system to the rest of the body. As this type of cancer becomes more common, the need for diagnosis, treatment, and management of the disease is expected to increase, thereby driving the growth of the neuroblastoma market.

 In addition to these, factors that are believed to fuel the market growth of neuroblastoma include increasing investments in the healthcare sector, the rising number of clinical trials, and the growing awareness about the disease among patients. Furthermore, an increasing success rate for cancer immunotherapy is further projected to enhance market growth. For instance, it has been estimated that 87% of children in the UK who have successfully completed immunotherapy have shown no evidence of disease last two years after completing the treatment. Also, five years after immunotherapy begins, approximately 78% of children in remission remain free of disease. The success rate of immunotherapy has been increasing owing to advancements in cancer research and the development of new drugs, which can help to improve the chances of survival for patients with neuroblastoma.

/admin/upload_images/Neuroblastoma Market.png
Get more information on this report: Request Free Sample PDF

Global Neuroblastoma Market: Key Insights


Base Year


Forecast Year




Base Year Market Size (2022)

~ USD 2,900 Million

Forecast Year Market Size (2035)

~ USD 5,100 Million

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)


Global Neuroblastoma Market: Growth Drivers and Challenges


Growth Drivers

  • Enhanced Survival Rates of Children Diagnosed with Neuroblastoma - For instance, a 5-year relative survival rate of more than 95% is achieved by children with low-risk neuroblastoma, and between 90% and 95% is achieved by children with intermediate-risk neuroblastoma. In children with neuroblastoma at high risk, the 5-year relative survival rate is approximately 50%. Since the introduction of effective treatments and therapies, the survival rate of children diagnosed with neuroblastoma has increased significantly. This has resulted in increased demand for treatments and therapies, driving growth in the neuroblastoma market.
  • Support And Funding from The Government for Children With Cancer- For instance, Lions Clubs International Foundation (LCIF) provides grants to projects that address the needs of children with cancer and their families. This can include financial assistance for medical costs, educational opportunities, and other supportive services. LCIF also works to increase public awareness of the needs of children with cancer and the importance of early detection and treatment of the disease.
  • Increasing Expenditures on Cancer Treatment- A significant proportion of U.S. healthcare expenditures is spent on cancer. Oncology health care in the U.S. is expected to grow to USD 246 billion by 2030, which is an increase of 34% over the 2015 amount of USD 183 billion spent in the U.S. on cancer health care.
  • Pharmacological Study of Targeted Drugs for Treating Neuroblastoma - There are now clinical trials examining new drugs targeting neuroblastoma cells more specifically than standard chemotherapy drugs. For instance, Crizotinib (Xalkori) is being studied for treating children with high-risk neuroblastoma when their cells display abnormal ALK gene sequences. In addition to lorlatinib (Lorbrena) and ceritinib (Zykadia), other drugs that target ALK-reactive cells are also being explored.
  • Drug Approvals by Regulatory Authorities For Cancer Treatment - For instance, on November 25, 2020, Naxitamab (Danyelza) has been approved by the US Food and Drug Administration (FDA) for the treatment of high-risk neuroblastoma cases. Research at Memorial Sloan Kettering's MSK Kids program contributed to the development of naxitamab (Danyelza).


  • Side effects associated with the treatments - Neuroblastoma treatments are often very harsh, with long-term effects on the patient's physical and mental health. These side effects can range from nausea and fatigue to memory loss and cognitive impairment, which can all have a negative impact on quality of life.
  • Lack of awareness about the condition and its symptoms
  • High cost of treatment and limited access to advanced therapies in developing economies

Global Neuroblastoma Market Segmentation

The global neuroblastoma market is segmented and analyzed for demand and supply by treatment type into chemotherapy, immunotherapy, and others. Out of these, the chemotherapy segment is estimated to gain the largest market share of about ~37% in the year 2035. The growth of the segment can be attributed to the rising investments in research and development activities for the development of new chemotherapeutic drugs. Furthermore, the increasing number of clinical trials for the development of advanced chemotherapeutic agents is further expected to fuel the growth of the segment. For instance, a variety of advanced therapeutic agents are being developed, including alkylating agents, antimetabolites, antimicrotubular agents, as well as antibiotics like actinomycin D, bleomycin, and daunomycin. Additionally, chemotherapy has been the mainstay of treatment for neuroblastoma and is expected to remain so in the near future.

The global neuroblastoma market is segmented and analyzed for demand and supply by product type into tablets, vaccines, and others. Out of these, the tablets segment is estimated to gain a significant market share of about ~39% in the year 2035. The tablets segment has seen tremendous growth owing to the ease of administration, better efficacy and safety profiles, and increased affordability compared to other product types. Furthermore, the emergence of precision medicine has also contributed to the growth of this segment as it is able to provide personalized drug therapies tailored to individual patients’ needs. Tablet dosage forms have higher bioavailability, meaning that more of the active ingredients are absorbed into the bloodstream, thus providing more effective treatments with fewer side effects. Additionally, tablets are easy to store, handle, and transport, making them more cost-effective than other forms of product.

Our in-depth analysis of the global neuroblastoma market includes the following segments:

     By Treatment Type

  • Chemotherapy
  • Immunotherapy
  • Others

    By Product Type

  • Tablets
  • Vaccines
  • Others

    By Distribution Channel

  • Online
  • Offline

    By End User

  • Hospitals
  • Clinics

Global Neuroblastoma Market Regional Synopsis


The market share of neuroblastoma in North America, amongst the market in all the other regions, is projected to be the largest with a share of about ~37% by the end of 2035. The growth of the market can be attributed majorly to the rising prevalence of neuroblastoma cancer, increasing healthcare expenditure, and the rising number of hospitals in the region. It is believed that neuroblastoma poses the greatest threat to infants (under a year of age). The American Cancer Society estimates that there are 700 to 800 new cases of neuroblastoma each year in the United States. Additionally, the region's increasing awareness of effective treatments and the availability of advanced diagnostic imaging techniques and targeted therapies are contributing to the market's growth. This increased access to diagnostic imaging has improved efficiency and accuracy of disease diagnosis, which has ultimately led to improved patient outcomes and better quality of care.

The Asia Pacific neuroblastoma market is estimated to be the second largest, registering a share of about ~27% by the end of 2035. The growth of the market can be attributed majorly to the growing awareness about the disease, increasing demand for advanced treatments, and the presence of numerous biopharmaceutical companies in the region. Furthermore, the increasing focus on research & development activities in the region is also expected to aid the growth of the neuroblastoma market. The increased healthcare infrastructure and public support allows for more accessible healthcare, which leads to higher life expectancies and better quality of life. Additionally, government initiatives and investments designed to increase access to healthcare are also contributing factors. These include initiatives to expand healthcare coverage to rural and low-income communities, as well as initiatives to increase the number of healthcare professionals working in the region.

Further, the neuroblastoma market in Europe, amongst the market in all the other regions, is projected to hold a majority of the share by the end of 2035. The growth of the market can be attributed majorly to the rising prevalence of the disease, increasing initiatives by the government to promote research and development, and the increasing availability of advanced diagnostic technologies. According to the research, there are approximately 100 children in the UK who are affected by Neuroblastoma each year. Additionally, the government has been introducing various initiatives and programs to increase research and development activities in this field in order to find better treatments for the disease. Furthermore, the increasing availability of advanced diagnostic technologies has enabled earlier and more accurate diagnosis of this disease. This has also contributed to the growth of the market.

/admin/upload_images/Neuroblastoma Market Size.png
Get more information on this report: Request Free Sample PDF

Top Featured Companies Dominating the Global Neuroblastoma Market

    • Merck & Co., Inc.,
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Pfizer Inc.
    • United Therapeutics Corporation
    • APEIRON Biologics AG
    • Sanofi S.A.
    • Bayer AG
    • Sun Pharmaceutical Industries Ltd.
    • Y- mabs Therapeutics Inc.
    • Baxter International Inc.
    • Cellectar Biosciences


In The News

  • An acquisition of Acceleron Pharma Inc., by Merck & Co., has been successfully completed. Merck & Co. sought to acquire Acceleron Pharma Inc. in order to expand its portfolio of biopharmaceuticals and build on its current capabilities in the biopharma space. The acquisition will give Merck & Co. access to Acceleron Pharma Inc.'s pipeline of potential new medicines and technologies, as well as provide the ability to better serve patients around the world.
  • An agreement has been signed by Pfizer Inc. and Seagen Inc. whereby Pfizer intends to acquire Seagen, a global biotechnology company focused on discovering, developing, and commercializing transformative cancer medicines, with a total enterprise value of USD 43 billion for each Seagen share at USD 229 in cash.


Global Economic Impact

Request Insights
Despite Inflation & Fearing Recession, Businesses Across the Globe Expected to Do Better in 2023:

In 2023, market players might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain.
Controlling Inflation has become the first priority for global economies from last quarter of 2022 and to be followed in 2023. With skewed economic situations, rise in interest rate by governments to control spending and inflation, spiked oil and gas prices, high inflation, geo-political issues including U.S. & China trade war, Russia-Ukraine conflict to intensify the global economic issues.
The interest rates in the U.S. may be less sensitive in 2023 as compared to 2022; sigh of relief for businesses. Positive business sentiments, healthy business balance sheets, growth in construction spending (private construction value in 2022 stood at $1,429.2 billion, 11.7 percent (±1.0 percent) above the $1,279.5 billion spent in 2021, Residential construction in 2022 was $899.1 billion, up by 13.3 percent (±2.1 percent) from $793.7 billion in 2021, non-residential construction touched $530.1 billion, 9.1 percent (±1.0 percent) above the $485.8 billion in 2021.) showcases minimal impact of recession in the country.
Similarly, spiked spending in the European and major Asia economics including, India, China & Japan to showcase less impact on the global demand.

Author Credits:  Radhika Gupta, Shivam Bhutani

Key Questions Answered in the Report

1) What are the major factors driving the growth of the neuroblastoma market?

Ans: Increasing prevalence of neuroblastoma, the growing awareness about the disease, and the availability of new treatments are the major factors driving the market growth.

2) What would be the CAGR of neuroblastoma market over the forecast period?

Ans: The market size of neuroblastoma is anticipated to attain a CAGR of ~4% over the forecast period, i.e., 2023 – 2035.

3) What are the challenges affecting the neuroblastoma market growth?

Ans: Lack of awareness about the condition and its symptoms, as well as the side effects associated with the treatments are estimated to be the growth hindering factors for the market expansion.

4) Which region will provide more business opportunities for growth of neuroblastoma market in future?

Ans: The market in the North America region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

5) Who are the major players dominating the neuroblastoma market?

Ans: The major players in the market are Merck & Co., Inc., Pfizer Inc., United Therapeutics Corporation, APEIRON Biologics AG, Sanofi S.A., Bayer AG, Sun Pharmaceutical Industries Ltd., Y- mabs Therapeutics Inc., Baxter International Inc., Cellectar Biosciences and others.

6) How are the company profiles selected?

Ans: The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.

7) What are the segments in the neuroblastoma market?

Ans: The market is segmented by treatment type, product type, distribution channel, end user and by region.

8) Which segment captures the largest market size in the treatment type segment in the neuroblastoma market?

Ans: The chemotherapy segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.

Let Us Hear About Your Requirements:

Submit Your Request For Proposal (RFP)

 Request Free Sample Copy